Insulet (NASDAQ:PODD) Price Target Raised to $172.00

Insulet (NASDAQ:PODD) had its price target increased by equities researchers at Wells Fargo & Company from $144.00 to $172.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 5.64% from the company’s previous close.

A number of other brokerages have also recently commented on PODD. Truist Financial cut shares of Insulet from a “buy” rating to a “hold” rating and cut their price target for the stock from $210.00 to $153.00 in a research note on Wednesday, August 5th. BTIG Research lowered Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Sanford C. Bernstein lowered their price objective on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen cut Insulet from a “buy” rating to a “hold” rating in a report on Saturday, October 24th. Finally, JPMorgan Chase & Co. downgraded Insulet from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $275.00 to $152.00 in a research report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $188.20.

Insulet Price Performance

Shares of NASDAQ:PODD traded down $2.20 during midday trading on Thursday, reaching $162.82. 59,780 shares of the company’s stock were exchanged, compared to its average volume of 1,391,950. The company’s 50 day simple moving average is $141.65 and its two-hundred day simple moving average is $178.00. The firm has a market capitalization of $11.29 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue was up 19.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 EPS. Equities research analysts expect that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Trading of Insulet

Several large investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC acquired a new position in shares of Insulet in the 2nd quarter worth approximately $6,741,000. Headlands Technologies LLC grew its position in Insulet by 2,041.5% during the 2nd quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier’s stock worth $4,861,000 after acquiring an additional 30,439 shares during the last quarter. Amundi increased its holdings in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after purchasing an additional 60,929 shares in the last quarter. SEB Asset Management AB acquired a new stake in Insulet during the 1st quarter valued at $24,700,000. Finally, Man Group plc acquired a new stake in Insulet during the 2nd quarter valued at $78,746,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q3 adjusted earnings were $1.99 per share, above the $1.59 consensus estimate, while revenue rose 19.2% year over year to $842 million, also exceeding expectations. The earnings call highlighted growth and margin expansion. Insulet Reports Strong Third-Quarter Growth and Margin Expansion
• Positive Sentiment: Insulet announced a $1 billion share-buyback authorization, which may support shareholder returns and signals confidence in the business. Insulet announces a $1 billion equity buyback
• Positive Sentiment: Reports said the company raised its 2026 outlook; one account noted the full-year EPS outlook was maintained. CEO sees slower growth in 2027 Insulet Q3 earnings and 2026 EPS outlook
• Negative Sentiment: Management expects growth to slow in 2027 and said rivals could take some share from Omnipod, raising concerns about the company’s future growth trajectory. CEO sees slower growth in 2027 and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.